Our findings of CDH1 and CDH3 promoter hypermethylation in NSCLC tumors, with relatively stable methylation for CDH2, are consistent with studies in gastric and prostate cancers (Pistore et al., 2017; Berx & Van Roy, 2009). The gene discussed is CDH2; the disease is prostate cancer.